Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing Nona's Harbour Mice platform, the collaboration aims to accelerate antibody discovery, focusing on innovative therapies for retinal and other eye conditions.

ACELYRIN will not make any additional internal investment in developing izokibep.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

Recognition may translate into policy changes and behavioral improvement.

The annual meeting brought announcements and insights from companies in the retina care space.

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries.

Data show promising early improvements in low luminance visual acuity, a key measure of visual function.

The report is titled, Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.

Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used hair dyes.

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations.

Nerve cells in the retina were analyzed at the Vienna University of Technology using microelectrodes. According to researchers, the nerve cells demonstrated surprisingly stable behavior, which is good news for retina implants.

The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports with an association between RVO and heart attack risk.

ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8.

Kim served the Samsung Bioepis as Development Division Leader since December 2021.

The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.

This virtual key opinion leader (KOL) event will take place on Wednesday, December 11, 2024, at 4:00 PM ET.

EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients. Topline data is anticipated in 2026.

The Foundation has assembled a multidisciplinary team of leading scientists, researchers, and physicians from multiple institutions, all focused on accelerating convergent technologies.

This service will provide researchers with tailored animal models that closely mimic human ocular conditions.

The trial is expected to close randomization in early December 2024.

The presentation and the moderated Q&A is scheduled for Tuesday, December 3, 2024 in Presentation Room 3 at 1:30 pm ET.

Sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy.

The organization will provide resources for spreading awareness and educating patients and care givers.